Robert Evan Reiter, M.D.

Office Address:
10833 Le Conte Ave.
BOX 951738,
Los Angeles, CA 90095

Work Address:
66-134 CHS
CAMPUS - 173818

Urological Research, Prostate Research and Treatment Program
Director, JCCC Genitourinary Oncology Program Area
Professor, Urology
Physician, Bladder Cancer Program, Kidney Cancer Program, Testicular Cancer Program
Member, CTSI
Research Interests
Interests: Prostate cancer, urologic oncology My laboratory interest in the basic molecular biology of urologic cancers and the translation of these discoveries to the clinical care of patients. Over the past few years, our laboratory has focused on three interrelated areas (1)the discovery of novel cell surface and secreted proteins associated with prostate cancer progression (2) the development of therapies directed against these targets, and (3) development of animal models of prostate and bladder cancer. A primary example of these three areas is our work related to prostate stem cell antigen (PSCA), a cell surface antigen which is overexpressed in a large percentage of prostate and bladder cancers. This gene was discovered by subtractive hybridization of xenografted prostate cancers developed at UCLA. Monoclonal antibodies against PSCA were generated and shown to inhibit prostate cancer in preclinical models. We are currently studying the mechanism by which these antibodies inhibit tumor formation and metastasis. We have also used these antibodies to study epithelial lineages within the normal prostate, hypothesizing that PSCA may mark a lineage associated with prostate carcinogenesis. Finally, we have asked whether the PSCA promoter can be used to target marker genes and oncogenes to the prostate (and bladder). Our first study, in collaboration with Owen Witte’s laboratory, demonstrated that the PSCA promoter can drive green fluorescent protein expression to a unique subset of prostate epithelial cells associated with prostate growth and cancer formation. We are currently expanding these studies to develop novel transgenic models of prostate (and bladder) cancer. Finally, we continue to identify additional genes potentially important in prostate and bladder cancer progression, which we hope to put through similar paradigms as described for PSCA.

Dr. Reiter is Professor and Bing Chair in Urologic Oncology in the Department of Urology, a member of the Molecular Biology Institute and JCCC. He leads the Prostate Cancer Program and has been PI of UCLA's Prostate Cancer SPORE program since 2007. His research is focused on molecular and functional imaging of prostate cancer, the discovery of novel targets for therapy and diagnosis, and the mechanisms by which prostate cancers evade current therapeutic approaches. He also is Assistant Dean of Bio-entrepreneurship in the DGSOM where he helps lead a faculty advisory to the newly established DGSOM Accelerator.


A selected list of publications:

Seiler Daniel, Zheng Junying, Liu Gentao, Wang Shunyou, Yamashiro Joyce, Reiter Robert E, Huang Jiaoti, Zeng Gang   Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines The Prostate, 2013; .
Sonn Geoffrey A, Chang Edward, Natarajan Shyam, Margolis Daniel J, Macairan Malu, Lieu Patricia, Huang Jiaoti, Dorey Frederick J, Reiter Robert E, Marks Leonard S   Value of Targeted Prostate Biopsy Using Magnetic Resonance-Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen European urology, 2013; .
Nagarajan Rajakumar, Margolis Daniel, Raman Steven, Sheng Ke, King Christopher, Reiter Robert, Thomas M Albert   Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer Advances in urology, 2012; 2012(3): 374805.
Finley David S, Ellingson Benjamin M, Natarajan Shyam, Zaw Taryar M, Raman Steve S, Schulam Peter, Reiter Robert E, Margolis Daniel   Diffusion tensor magnetic resonance tractography of the prostate: feasibility for mapping periprostatic fibers Urology, 2012; 80(1): 219-23.
Nagarajan Rajakumar, Margolis Daniel, Raman Steven, Sarma Manoj K, Sheng Ke, King Christopher R, Verma Gaurav, Sayre James, Reiter Robert E, Thomas M Albert   MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores Journal of magnetic resonance imaging : JMRI, 2012; 36(3): 697-703.
McClure Timothy D, Margolis Daniel J A, Reiter Robert E, Sayre James W, Thomas M Albert, Nagarajan Rajakumar, Gulati Mittul, Raman Steven S   Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy Radiology, 2012; 262(3): 874-83.
Finley David S, Margolis Daniel, Raman Steve S, Ellingson Benjamin M, Natarajan Shyam, Tan Nelly, Huang Jiaoti, Reiter Robert E   Fine-tuning robot-assisted radical prostatectomy planning with MRI Urologic oncology, 2011; 2012(3): .
Goldstein Andrew S, Drake Justin M, Burnes Daina L, Finley David S, Zhang Hong, Reiter Robert E, Huang Jiaoti, Witte Owen N   Purification and direct transformation of epithelial progenitor cells from primary human prostate Nature protocols, 2011; 6(5): 656-67.
Tan Nelly, Margolis Daniel J A, McClure Timothy D, Thomas Albert, Finley David S, Reiter Robert E, Huang Jiaoti, Raman Steven S   Radical prostatectomy: value of prostate MRI in surgical planning Abdominal imaging, 2011; .
Wallerand Hervé, Bernhard Jean-Christophe, Culine Stéphane, Ballanger Philippe, Robert Grégoire, Reiter Robert E, Ferrière Jean-Marie, Ravaud Alain   Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways Urologic oncology, 2011; 29(1): 4-11.
Lepin Eric J, Leyton Jeffrey V, Zhou Yu, Olafsen Tove, Salazar Felix B, McCabe Katelyn E, Hahm Scott, Marks James D, Reiter Robert E, Wu Anna M   An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors European journal of nuclear medicine and molecular imaging, 2010; 37(8): 1529-38.
Garraway Isla P, Sun Wenyi, Tran Chau P, Perner Sven, Zhang Bao, Goldstein Andrew S, Hahm Scott A, Haider Maahum, Head Christian S, Reiter Robert E, Rubin Mark A, Witte Owen N   Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo The Prostate, 2010; 70(5): 491-501.
Tanaka Hiroshi, Kono Evelyn, Tran Chau P, Miyazaki Hideyo, Yamashiro Joyce, Shimomura Tatsuya, Fazli Ladan, Wada Robert, Huang Jiaoti, Vessella Robert L, An Jaibin, Horvath Steven, Gleave Martin, Rettig Matthew B, Wainberg Zev A, Reiter Robert E   Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance Nature medicine, 2010; 16(12): 1414-20.
Wallerand Hervé, Robert Grégoire, Pasticier Gilles, Ravaud Alain, Ballanger Philippe, Reiter Robert E, Ferrière Jean-Marie   The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers Urologic oncology, 2010; 28(5): 473-9.
Leyton Jeffrey V, Olafsen Tove, Sherman Mark A, Bauer Karl B, Aghajanian Patrick, Reiter Robert E, Wu Anna M   Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors Protein engineering, design & selection : PEDS, 2009; 22(3): 209-16.
Gore John L, Kwan Lorna, Lee Steve P, Reiter Robert E, Litwin Mark S   Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer Journal of the National Cancer Institute, 2009; 101(12): 888-92.
Fondrevelle Marie E, Kantelip Bernadette, Reiter Robert E, Chopin Dominique K, Thiery Jean P, Monnien Franck, Bittard Hugues, Wallerand Hervé   The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status Urologic oncology, 2009; 27(3): 268-76.
Reiter Robert E   The urologist role in basic and clinical translational research: Personal reflections of a urologic scientist Urologic oncology, 2009; 27(2): 127-8.
Hara Takahito, Miyazaki Hideyo, Lee Aram, Tran Chau P, Reiter Robert E   Androgen receptor and invasion in prostate cancer Cancer research, 2008; 68(4): 1128-35.
Moore Miranda L, Teitell Michael A, Kim Yoon, Watabe Tetsuro, Reiter Robert E, Witte Owen N, Dubey Purnima   Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation The Prostate, 2008; 68(2): 139-51.
Leyton Jeffrey V, Olafsen Tove, Lepin Eric J, Hahm Scott, Bauer Karl B, Reiter Robert E, Wu Anna M   Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors Clinical cancer research : an official journal of the American Association for Cancer Research, 2008; 14(22): 7488-96.
van de Poll-Franse Lonneke V, Kwan Lorna, Reiter Robert E, Lee Steve P, Litwin Mark S   The influence of cardiovascular disease on health related quality of life in men with prostate cancer: a 4-year followup study The Journal of urology, 2008; 179(4): 1362-7; discussion 1367.
Pariente Nonia, Morizono Kouki, Virk Mandeep S, Petrigliano Frank A, Reiter Robert E, Lieberman Jay R, Chen Irvin S Y   A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration Molecular therapy : the journal of the American Society of Gene Therapy, 2007; 15(11): 1973-81.
Lin Kevin, Lee Steve P, Cho Jennifer S, Reiter Robert E, DeMarco John J, Solberg Timothy D   Improvements in prostate brachytherapy dosimetry due to seed stranding Brachytherapy, 2007; 6(1): 44-8.
Litwin Mark S, Gore John L, Kwan Lorna, Brandeis Judson M, Lee Steve P, Withers H Rodney, Reiter Robert E   Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer Cancer, 2007; 109(11): 2239-47.
Olafsen Tove, Gu Zhennan, Sherman Mark A, Leyton Jeffrey V, Witkosky Michael E, Shively John E, Raubitschek Andrew A, Morrison Sherie L, Wu Anna M, Reiter Robert E   Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody Journal of immunotherapy (Hagerstown, Md. : 1997), 2007; 30(4): 396-405.
Reiter Robert E, Riggs Stephen   What factors affect the PSA relapse-free survival times in patients treated with permanent seed brachytherapy? Nature clinical practice. Urology, 2007; 4(12): 650-1.
Rao Dinesh S, Gui Dorina, Koski Michelle E, Popoviciu Laura M, Wang Hejing, Reiter Robert E, Said Jonathan W   An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry, 2006; 14(4): 375-83.
Lam John S, Reiter Robert E   Stem cells in prostate and prostate cancer development Urologic oncology, 2006; 24(2): 131-40.
Reiter Robert E, Shurtleff Benjamin   What are the operating characteristics of PSA screening for prostate cancer? Nature clinical practice. Urology, 2006; 3(2): 74-5.
Gu Zhennan, Yamashiro Joyce, Kono Evelyn, Reiter Robert E   Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism Cancer research, 2005; 65(20): 9495-500.
Wente Moritz N, Jain Anjali, Kono Evelyn, Berberat Pascal O, Giese Thomas, Reber Howard A, Friess Helmut, Büchler Markus W, Reiter Robert E, Hines Oscar J   Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer Pancreas, 2005; 31(2): 119-25.
Lam John S, Yamashiro Joyce, Shintaku I Peter, Vessella Robert L, Jenkins Robert B, Horvath Steve, Said Jonathan W, Reiter Robert E   Prostate stem cell antigen is overexpressed in prostate cancer metastases Clinical cancer research : an official journal of the American Association for Cancer Research, 2005; 11(7): 2591-6.
Gu Zhennan, Rubin Mark A, Yang Yu, Deprimo Samuel E, Zhao Hongjuan, Horvath Steven, Brooks James D, Loda Massimo, Reiter Robert E   Reg IV: a promising marker of hormone refractory metastatic prostate cancer Clinical cancer research : an official journal of the American Association for Cancer Research, 2005; 11(6): 2237-43.
Thomas George V, Horvath Steve, Smith Bradley L, Crosby Katherine, Lebel Lori A, Schrage Matthew, Said Jonathan, De Kernion Jean, Reiter Robert E, Sawyers Charles L   Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer Clinical cancer research : an official journal of the American Association for Cancer Research, 2004; 10(24): 8351-6.
Chin Jonathan L, Reiter Robert E   Genetic alterations in prostate cancer Current urology reports, 2004; 5(3): 157-65.
Chin Jonathan L, Reiter Robert E   Molecular markers and prostate cancer prognosis Clinical prostate cancer, 2004; 3(3): 157-64.
Han Ken-Ryu, Seligson David B, Liu Xueli, Horvath Steve, Shintaku Peter I, Thomas George V, Said Jonathan W, Reiter Robert E   Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer The Journal of urology, 2004; 171(3): 1117-21.
Garraway Isla P, Seligson David, Said Jonathan, Horvath Steve, Reiter Robert E   Trefoil factor 3 is overexpressed in human prostate cancer The Prostate, 2004; 61(3): 209-14.
Cheng Lirong, Reiter Robert E, Jin Yusheng, Sharon Hirschowitz, Wieder Jeffrey, Lane Timothy F, Rao Jianyu   Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens The Journal of urology, 2003; 169(6): 2094-100.
Christiansen Jason J, Rajasekaran Sigrid A, Moy Peggy, Butch Anthony, Goodglick Lee, Gu Zhennan, Reiter Robert E, Bander Neil H, Rajasekaran Ayyappan K   Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line The Prostate, 2003; 55(1): 9-19.
Freedland Stephen J, de Gregorio Frank, Sacoolidge John C, Elshimali Yahya I, Csathy George S, Elashoff David A, Reiter Robert E, Aronson William J   Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression Urology, 2003; 61(6): 1187-92.
Freedland Stephen J, deGregorio Frank, Sacoolidge John C, Elshimali Yahya I, Csathy George S, Dorey Frederick, Reiter Robert E, Aronson William J   Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy The Journal of urology, 2003; 169(4): 1325-30.
Watabe Tetsuro, Lin Mark, Ide Hisamitsu, Donjacour Annemarie A, Cunha Gerald R, Witte Owen N, Reiter Robert E   Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter Proceedings of the National Academy of Sciences of the United States of America, 2002; 99(1): 401-6.
Jain Anjali, Lam Amanda, Vivanco Igor, Carey Michael F, Reiter Robert E   Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene Molecular endocrinology (Baltimore, Md.), 2002; 16(10): 2323-37.
Watabe T, Lin M, Donjacour AA, Cunha G, Witte ON, Reiter RE   In situ visualization of a growth responsive subset of epithelial cell associated with prostate development, regeneration and tumorigenesis, PNAS, 2002; 99: 401.
Palapattu Ganesh S, Reiter Robert E   Monoclonal antibody therapy for genitourinary oncology: promise for the future The Journal of urology, 2002; 168(6): 2615-23.
Tran Chau P, Lin Connie, Yamashiro Joyce, Reiter Robert E   Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells Molecular cancer research : MCR, 2002; 1(2): 113-21.
Jalkut Mark W, Reiter Robert E   Role of prostate stem cell antigen in prostate cancer research Current opinion in urology, 2002; 12(5): 401-6.
DePrimo Samuel E, Diehn Maximilian, Nelson Joel B, Reiter Robert E, Matese John, Fero Mike, Tibshirani Robert, Brown Patrick O, Brooks James D   Transcriptional programs activated by exposure of human prostate cancer cells to androgen Genome biology, 2002; 3(7): RESEARCH0032.
Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A   Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts Proceedings of the National Academy of Sciences of the United States of America. , 2001; 98(5): 2658-63.
Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE   Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer Oncogene. , 2000; 19(10): 1288-96.